AbbVie beats estimates but stock dips
AbbVie (NYSE:ABBV) reported Q3 earnings of $3.82 per share, beating estimates by $0.08, with revenue of $17.4B, up 10.3% YoY. The company raised its 2026 EPS guidance to $13.95-$13.99, in line with consensus. Shares fell 3% premarket. Key drugs like Skyrizi and Rinvoq drove growth, while Humira sales declined 31.2%. AbbVie also increased its quarterly dividend by 5.2%.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise are modest; market reaction is a 3% pre‑market decline, indicating investors may be pricing in concerns over Humira decline and R&D expenses.
Market read
First‑report earnings data for a large‑cap pharma company with immediate price impact.
What to watch
The 5.2% dividend increase and acquisition of Apogee Therapeutics could support longer‑term upside.
Background
AbbVie posted Q3 adjusted EPS of $3.82 vs $3.74 estimate and revenue of $17.4B vs $17.36B estimate, raising FY2026 EPS guidance to $13.95‑$13.99.
Ticker impact
AbbVie reported Q3 earnings beat and raised FY2026 EPS guidance, but shares fell 3% pre‑market.
likely pressure as the market prices in the guidance that is only marginally above consensus and the stock already slipped 3% pre‑market.
First‑report earnings data with concrete numbers for EPS, revenue, and guidance; large‑cap impact; immediate price reaction.
Market effects
Pharma sector may see modest pullback as AbbVie's guidance aligns with consensus, limiting upside for peers.
U.S. large‑cap healthcare index could face slight downside pressure.
Limited; primarily U.S. market impact.
Counterpoint
Guidance is in line with expectations; the dip may be an overreaction, presenting a buying opportunity.
Key entities
- companyAbbVie Inc.
Pharmaceutical company reporting Q3 results.
